vivotif enteric-coated capsule
propharm (m) sdn. bhd. - attenuated typhoid bacilli; attenuated typhoid bacilli; attenuated typhoid bacilli -
bovilis ringvac lyophilisate and solvent for suspension for injection for cattle
intervet ireland limited - attenuated micronidia of trichophyton verrucosum strain ltf-130; attenuated micronidia of trichophyton verrucosum strain ltf-130; attenuated micronidia of trichophyton verrucosum strain ltf-130 - lyophilisate and solvent for suspension for injection - . - trichophyton
fluenz tetra
astrazeneca ab - a/darwin/9/2021 (h3n2) - like strain (a/norway/16606/2021, medi 355293) / a/victoria/2570/2019 (h1n1)pdm09 - like strain (a/victoria/1/2020, medi 340505) / b/austria/1359417/2021 - like strain (b/austria/1359417/2021, medi 355292) / b/phuket/3073/2013 - like strain (b/phuket/3073/2013, medi 306444) - influenza, human - influenza vaccines, influenza, live attenuated - prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. the use of fluenz tetra should be based on official recommendations.
m-m-r ii powder for solution
merck canada inc - measles virus vaccine live attenuated; mumps virus vaccine live attenuated (jeryl lynn strain); rubella virus vaccine live attenuated (wistar ra27/3 strain) - powder for solution - 1000unit; 5000unit; 1000unit - measles virus vaccine live attenuated 1000unit; mumps virus vaccine live attenuated (jeryl lynn strain) 5000unit; rubella virus vaccine live attenuated (wistar ra27/3 strain) 1000unit - vaccines
nobilis cav p4 vaccine
intervet australia pty limited - chicken anaemia virus (living, attenuated) strain 26p4 - misc. vaccines or anti sera - chicken anaemia virus (living, attenuated) strain 26p4 vaccine-viral active 0.0 undefined - immunotherapy - chicken progeny - cav disease
varilrix
glaxo smith kline (israel) ltd - varicella virus, live attenuated - powder and solvent for solution for injection - varicella virus, live attenuated nlt 10^3.3 pfu - varicella zoster vaccines - varilrix is intended for the active immunization against varicella of the categories of persons listed below, where there is no history of varicella.- healthy subjects, from the age of 12 months.- patients at high risk of severe varicella, such as patients with acute leukemia or a chronic condition, those on immunosuppressive therapy or those for whom an organ transplant is being considered.healthy persons living in close contact with patients with varicella and high-risk patients.
varivax > 1350 pfu pdr+solv for susp for inj
sanofi pasteur msd ltd - varicella virus (oka strain) live attenuated - pdr+solv for susp for inj - > 1350 pfu - varicella zoster vaccines
priorix-tetra
glaxosmithkline pte ltd - live attenuated measles virus (schwarz strain); live attenuated mumps virus (rit4385 strain); live attenuated rubella virus (wistar ra 27/3 strain); live attenuated varicella virus (oka strain) - injection, powder, lyophilized, for solution - ≥ 10 3.0 ccid50 /dose - live attenuated measles virus (schwarz strain) ≥ 10³ ccid50/dose; live attenuated mumps virus (rit4385 strain) ≥ 10⁴·⁴ ccid50/dose; live attenuated rubella virus (wistar ra 27/3 strain) ≥ 10³ ccid50/dose; live attenuated varicella virus (oka strain) ≥ 10³·³ pfu/dose
rotarix oral suspension (oral applicator)
glaxosmithkline pte ltd - human rotavirus, live, attenuated, rix 4414 strain - suspension - not less than 10⁶ ccid₅₀/dose (1.5 ml) - human rotavirus, live, attenuated, rix 4414 strain not less than 10⁶ ccid₅₀/dose (1.5 ml)
imojev® powder and diluent for suspension for injection
zuellig pharma pte. ltd. - japanese encephalitis virus (live, attenuated, recombinant) - injection, powder, lyophilized, for suspension - 4.0-5.8 log pfu/dose - japanese encephalitis virus (live, attenuated, recombinant) 4.0-5.8 log pfu/dose